PROTHENA CORP PLC (PRTA)
IE00B91XRN20 - Common Stock
PRTA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While PRTA has a great health rating, there are worries on its profitability. PRTA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PRTA has reported negative net income.
PRTA had a negative operating cash flow in the past year.
PRTA had negative earnings in 4 of the past 5 years.
PRTA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PRTA has a Return On Assets of -22.15%. This is in the better half of the industry: PRTA outperforms 75.04% of its industry peers.
PRTA has a better Return On Equity (-24.67%) than 81.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.15% | ||
| ROE | -24.67% | ||
| ROIC | N/A |
ROA(3y)-8.51%
ROA(5y)-15.49%
ROE(3y)-10.2%
ROE(5y)-23.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PRTA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRTA has more shares outstanding
PRTA has more shares outstanding than it did 5 years ago.
PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PRTA has an Altman-Z score of 6.31. This indicates that PRTA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.31, PRTA belongs to the top of the industry, outperforming 83.01% of the companies in the same industry.
There is no outstanding debt for PRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.31 |
ROIC/WACCN/A
WACC7.23%
2.3 Liquidity
A Current Ratio of 11.52 indicates that PRTA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 11.52, PRTA belongs to the top of the industry, outperforming 84.96% of the companies in the same industry.
A Quick Ratio of 11.52 indicates that PRTA has no problem at all paying its short term obligations.
PRTA's Quick ratio of 11.52 is amongst the best of the industry. PRTA outperforms 84.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.52 | ||
| Quick Ratio | 11.52 |
3. Growth
3.1 Past
The earnings per share for PRTA have decreased strongly by -74.65% in the last year.
Looking at the last year, PRTA shows a decrease in Revenue. The Revenue has decreased by -5.43% in the last year.
PRTA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 146.70% yearly.
EPS 1Y (TTM)-74.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-389.47%
Revenue 1Y (TTM)-5.43%
Revenue growth 3Y366.5%
Revenue growth 5Y146.7%
Sales Q2Q%-98.86%
3.2 Future
Based on estimates for the next years, PRTA will show a very strong growth in Earnings Per Share. The EPS will grow by 29.03% on average per year.
Based on estimates for the next years, PRTA will show a very strong growth in Revenue. The Revenue will grow by 50.85% on average per year.
EPS Next Y17.91%
EPS Next 2Y-21%
EPS Next 3Y1.6%
EPS Next 5Y29.03%
Revenue Next Year45.96%
Revenue Next 2Y-6.73%
Revenue Next 3Y28.66%
Revenue Next 5Y50.85%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21%
EPS Next 3Y1.6%
5. Dividend
5.1 Amount
PRTA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROTHENA CORP PLC
NASDAQ:PRTA (12/20/2024, 8:00:01 PM)
After market: 15.1 -0.12 (-0.79%)15.22
-0.79 (-4.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.63%
Inst Owner Change-0.03%
Ins Owners0.04%
Ins Owner Change0%
Market Cap818.99M
Analysts81.43
Price Target61.64 (304.99%)
Short Float %17.3%
Short Ratio16.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)110.98%
Min EPS beat(2)8.41%
Max EPS beat(2)213.55%
EPS beat(4)2
Avg EPS beat(4)52.77%
Min EPS beat(4)-9.36%
Max EPS beat(4)213.55%
EPS beat(8)5
Avg EPS beat(8)69.78%
EPS beat(12)5
Avg EPS beat(12)31.77%
EPS beat(16)6
Avg EPS beat(16)16.69%
Revenue beat(2)1
Avg Revenue beat(2)541.99%
Min Revenue beat(2)-22.4%
Max Revenue beat(2)1106.38%
Revenue beat(4)1
Avg Revenue beat(4)225.16%
Min Revenue beat(4)-97.74%
Max Revenue beat(4)1106.38%
Revenue beat(8)3
Avg Revenue beat(8)123.01%
Revenue beat(12)3
Avg Revenue beat(12)51.89%
Revenue beat(16)4
Avg Revenue beat(16)39.38%
PT rev (1m)-1.17%
PT rev (3m)-1.64%
EPS NQ rev (1m)-1.18%
EPS NQ rev (3m)-1.18%
EPS NY rev (1m)3.4%
EPS NY rev (3m)1.95%
Revenue NQ rev (1m)-26.5%
Revenue NQ rev (3m)-26.5%
Revenue NY rev (1m)-8.93%
Revenue NY rev (3m)-8.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.14 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.53 | ||
| P/tB | 1.53 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.48
EYN/A
EPS(NY)-4.1
Fwd EYN/A
FCF(TTM)-2.88
FCFYN/A
OCF(TTM)-2.85
OCFYN/A
SpS2.48
BVpS9.93
TBVpS9.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.15% | ||
| ROE | -24.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-8.51%
ROA(5y)-15.49%
ROE(3y)-10.2%
ROE(5y)-23.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 196.11% | ||
| Cap/Sales | 1.32% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.52 | ||
| Quick Ratio | 11.52 | ||
| Altman-Z | 6.31 |
F-Score2
WACC7.23%
ROIC/WACCN/A
Cap/Depr(3y)138.92%
Cap/Depr(5y)93.18%
Cap/Sales(3y)1.41%
Cap/Sales(5y)19.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-389.47%
EPS Next Y17.91%
EPS Next 2Y-21%
EPS Next 3Y1.6%
EPS Next 5Y29.03%
Revenue 1Y (TTM)-5.43%
Revenue growth 3Y366.5%
Revenue growth 5Y146.7%
Sales Q2Q%-98.86%
Revenue Next Year45.96%
Revenue Next 2Y-6.73%
Revenue Next 3Y28.66%
Revenue Next 5Y50.85%
EBIT growth 1Y-49.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.61%
EBIT Next 3Y-23.6%
EBIT Next 5YN/A
FCF growth 1Y-22.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.36%
OCF growth 3YN/A
OCF growth 5YN/A